Federal health officials will invest nearly $100 million to develop a new antibiotic that can treat drug-resistant “superbugs” for which there are currently few or no treatment options.

HHS will collaborate with the Defense Department and Malvern, Pa.-based drugmaker VenatoRx Pharmaceuticals on the company’s compound VNRX-5133. When combined with the intravenous antibiotic cefepime, the compound might combat bacteria that is resistant to currently available antibiotics, the agencies said Monday.

 

Credit: iStock, Fahroni

Read more…